Jin opens new horizons for the treatment of resistant ovarian cancer .. What is it?

In an important scientific discovery, a recent study published in Genes & Diseases revealed a new and decisive role for gene “XPR1” in promoting ovarian cancer growth, one of the most aggressive and difficult types of women’s cancer and difficulty in diagnosis and treatment.

The study was conducted by researchers from the Chongzing University Medical University in China, and highlighted how the “XPR1” gene contributed to resisting cancer cells of traditional immune treatments, through its interaction with specific cellular tracks, most notably the regulation of self -devotion and evasion of the immune system.

What is the “XPR1” gene?

The results showed that the level of XPR1 gene expression increases significantly in ovarian cancer cells compared to healthy cells, and this rise is associated with advanced stages of the disease and low survival rates.

Upon silence the gene, the growth of cancer cells slows down and its spread has declined, while excessive expression accelerated the growth of the tumor, proving its role in enhancing the aggression of the disease.

The relationship of the gene to the immune evasion

The study showed that XPR1 interacts with LAMP1 protein, which is a major ingredient in lyzozomat, to regulate self -devotion, a process by the cell by dismantling its damaged or unnecessary internal components.
This interaction, according to the study, plays an important role in hiding cancer cells from the immune system, by affecting the MHC-I proteins responsible for defining the deadly T cells to exotic bodies.

A step towards more effective immunotherapy

Interestingly, the incorporation of XPR1 genes with the use of chlorokin (self -accusative inhibitors) has enhanced the ability of the immune system to identify and kill cancer cells in animal models.
The growth of the tumor has also clearly decreased, indicating the possibility of developing more effective compound treatments in the future, especially for ovarian abayaever is resistant to traditional treatments.

This discovery opens the door to new therapeutic strategies based on targeting the XPR1 gene in parallel with the promotion of the immune system, which may pave the way for changing the rules of dealing with one of the deadly types of women’s cancer.

(Eurekalert and Genes & Diseases)